Creative Biolabs

Multiple Sclerosis

Multiple Sclerosis

Multiple sclerosis (MS), characterized by a proinflammatory and neurodegenerative process, is an inflammatory demyelinating disease of the central nervous system (CNS) that results in neuroaxonal damage. There are several types of MS, including Benign MS, Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary-Progressive MS (PPMS), and Malignant MS. Clinical expressions of MS vary depending on the locations of affected nerve fibers, but the most common symptoms are sensory loss, motor spinal cord symptoms, autonomic spinal cord symptoms, cerebellar symptoms, optic neuritis, trigeminal neuralgia, etc. Epidemiological data indicate that both genetic and environmental factors are important for the etiology of MS. Experimental autoimmune encephalomyelitis (EAE) is one of the most widely used models of MS. Besides, Theiler's murine encephalitis virus-induced demyelinating disease (TMEV-IDD) has been intensively used as a model for human demyelinating diseases, including MS. Demyelination induced in mice with a copper chelator cuprizone is also an important tool for MS studies.

B-cell mediated inflammatory pathway in MS. Fig.1 B-cell mediated inflammatory pathway in MS.

B cells are important in MS because of their efficient antigen-presenting abilities. They produce cytokines that can change the microenvironment and mediate the negative effects through astrocyte populations, and they produce antibodies with potential roles in targeting ectopic lymphoid follicle like aggregates that persist long term in the brains of MS patients. The understanding of the role of B cells in MS presents opportunities for developing effective therapies. Therapeutic monoclonal antibodies (mAbs) utilized in the treatment of MS and their molecular targets are shown in Fig.2.

Therapeutic mAbs utilized in the treatment of MS and their molecular targets. Fig.2 Therapeutic mAbs utilized in the treatment of MS and their molecular targets. (Dubey, 2015)

At Creative Biolabs, we have worked with some of the world-leading researchers, linking their invaluable insights to our scientific expertise to produce high-quality content across MS disease area. Creative Biolabs offers comprehensive products as well as high-quality customized services for our clients. We fully believe we have identified some of the best products and packages to aid your research, whilst also highlighting some of the most relevant current and future topics.

Summary of Popular Targets in Multiple Sclerosis

CD20 CD6
CD52 Muscarinic type 3 receptor (M3R)
CD25 IL-6R
α4-integrin C5 complement protein
VCAM1 VLA-2
TLR9 IL-17A
Leucine-rich repeat and immunoglobulin domain-containing neurite outgrowth inhibitor receptor-interacting protein-1 (LINGO-1)
Sphingosine-1-phosphate 1/5 receptors

Reference

  1. Dubey, D.; et al. Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert review of clinical immunology. 2015, 11(1): 93-108.

For Research Use Only. Not For Clinical Use.
Send Inquiry Send Inquiry
Inquiry Basket
compare

Go to compare